Addex Therapeutics focuses on the discovery and development of an emerging class of oral small molecule drugs that can be exquisitely selective for their intended target and confer significant therapeutic advantages over conventional “orthosteric” small molecule or biological drugs. ADDXF’s two lead products are being investigated in three phase IIa clinical studies: dipraglurant for the treatment of Parkinson’s disease levodopa-induced dyskinesia; and ADX71149 to treat schizophrenia and anxiety. For further information, visit the company’s Web site at www.addextherapeutics.com

EBD Group’s Biotech Showcase is an investor and partnering conference devoted to providing private and public biotechnology and life sciences companies with an opportunity to present to, and meet with, investors and pharmaceutical executives in one place during the course of one of the industry’s largest annual healthcare investor conferences. Investors and biopharmaceutical executives from around the world gather in San Francisco for this important event.

Let us hear your thoughts below: